Minerva Neurosciences, Inc. (NASDAQ: NERV) is a Healthcare company (Biotechnology) with a market capitalization of $108M. The Maz Rating grades it against the other companies in its sector.
Minerva Neurosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
Minerva Neurosciences, Inc. has been loss-making over the last twelve months, so it has no meaningful P/E. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of 167.7%, return on invested capital of -43.6% and a free cash flow yield of -29.0%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 33.02. Over the past 52 weeks the share price ranged from $1.96 to $8.80, with a beta of -0.12.
Minerva Neurosciences, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 5 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.